Health Care Innovation
Commentary
Trump’s Drug Pricing Order Is A Costly Mistake
On Sunday, September 13, President Trump signed a “most-favored-nation” executive order to reduce U.S. drug prices. It instructs federal officials to set pharmaceutical reimbursements under Medicare Parts B and D equal to the lowest prices paid in other developed countries, including Canada, the United Kingdom, and France. The high cost of medications is a ...
Blog
California Entering Pharmaceutical Business Won’t Lower Drug Prices for Patients
The state of California, which can’t keep the lights on thanks to political interference in energy generation, nor build enough homes because government has poisoned the housing market, is going into the pharmaceutical manufacturing business. But there’s nothing to worry about. If it struggles, taxpayers will be there to bail ...
Health Care
PRI Medical Billing Study Featured in Northern California Record
Title: AB 72 brief analyzes impact of medical billing reform law that’s had bad consequences for patients and practitioners By Sarah Downey, Northern California Record A new policy brief about the impact of California AB 72 finds that the law – designed to alleviate surprise medical billing – while well-intentioned ...
California
Read Revcycle Intelligence Story on Surprise Medical Billing Brief
Surprise Billing Price Controls Decreasing Care Quality in CA By: Jacqueline LaPointe, Reporter Researchers at the Pacific Research Institute are warning Congressmembers to steer clear from price controls as a solution for surprise billing after finding that the policy approach had unintended consequences in California. In a new brief, researchers found ...
California
New Brief Shows Impact of California’s Surprise Medical Billing Law: Lower Quality Care, Reduced Access, Higher System Costs
California’s surprise medical billing law (Assembly Bill 72) – which imposes price controls on the rates out-of-network physicians can charge at in-network facilities – is hurting patients with lower quality care, reduced access, and higher health care system costs, finds a new brief released today by the Center for Medical ...
Commentary
Kamala Harris’s harrowing healthcare history
Sen. Kamala Harris will be the Democratic Party’s nominee for vice president, we learned on Tuesday. The pick appears to be in line with former Vice President Joe Biden’s semi-moderate instincts. But on healthcare, Harris has proved anything but moderate. She has a long track record of support for government-run healthcare. ...
Commentary
Trump’s drug pricing executive orders harmful to patients — will hinder development of new drugs
President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price ...
Commentary
President Trump’s Big Government Instincts Threaten Drug Innovation And Availability
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the ...
Commentary
Executive Order On Drug Price Controls Would Backfire
Rumor has it that President Trump will soon issue a sweeping executive order to lower prescription drug prices by fiat. Nothing is set in stone. But the order would reportedly index the government’s reimbursements for medicines to the prices that Britain, France, Canada, and other developed nations pay. Since all those nations ...
Commentary
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Trump’s Drug Pricing Order Is A Costly Mistake
On Sunday, September 13, President Trump signed a “most-favored-nation” executive order to reduce U.S. drug prices. It instructs federal officials to set pharmaceutical reimbursements under Medicare Parts B and D equal to the lowest prices paid in other developed countries, including Canada, the United Kingdom, and France. The high cost of medications is a ...
California Entering Pharmaceutical Business Won’t Lower Drug Prices for Patients
The state of California, which can’t keep the lights on thanks to political interference in energy generation, nor build enough homes because government has poisoned the housing market, is going into the pharmaceutical manufacturing business. But there’s nothing to worry about. If it struggles, taxpayers will be there to bail ...
PRI Medical Billing Study Featured in Northern California Record
Title: AB 72 brief analyzes impact of medical billing reform law that’s had bad consequences for patients and practitioners By Sarah Downey, Northern California Record A new policy brief about the impact of California AB 72 finds that the law – designed to alleviate surprise medical billing – while well-intentioned ...
Read Revcycle Intelligence Story on Surprise Medical Billing Brief
Surprise Billing Price Controls Decreasing Care Quality in CA By: Jacqueline LaPointe, Reporter Researchers at the Pacific Research Institute are warning Congressmembers to steer clear from price controls as a solution for surprise billing after finding that the policy approach had unintended consequences in California. In a new brief, researchers found ...
New Brief Shows Impact of California’s Surprise Medical Billing Law: Lower Quality Care, Reduced Access, Higher System Costs
California’s surprise medical billing law (Assembly Bill 72) – which imposes price controls on the rates out-of-network physicians can charge at in-network facilities – is hurting patients with lower quality care, reduced access, and higher health care system costs, finds a new brief released today by the Center for Medical ...
Kamala Harris’s harrowing healthcare history
Sen. Kamala Harris will be the Democratic Party’s nominee for vice president, we learned on Tuesday. The pick appears to be in line with former Vice President Joe Biden’s semi-moderate instincts. But on healthcare, Harris has proved anything but moderate. She has a long track record of support for government-run healthcare. ...
Trump’s drug pricing executive orders harmful to patients — will hinder development of new drugs
President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price ...
President Trump’s Big Government Instincts Threaten Drug Innovation And Availability
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the ...
Executive Order On Drug Price Controls Would Backfire
Rumor has it that President Trump will soon issue a sweeping executive order to lower prescription drug prices by fiat. Nothing is set in stone. But the order would reportedly index the government’s reimbursements for medicines to the prices that Britain, France, Canada, and other developed nations pay. Since all those nations ...
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
